查詢結果分析
來源資料
相關文獻
- 脂肪肝的篩檢、診斷、臨床影響及治療
- Metabolic Disorders in Children and Adolescents with Type 2 Diabetes Mellitus
- Nonalcoholic Fatty Liver Disease Manifesting Esophageal Variceal Bleeding
- Hyperinsulinemia and Insulin Resistance Related Metabolic Syndrome
- Resistin:一種銜接肥胖症和糖尿病的新激素
- Childhood Obesity in Taiwan
- 極低熱量飲食能有效地改善控制不佳的肥胖糖尿病
- 糖尿病患者之脂質代謝異常
- 非肥胖性糖尿病(NOD/LtJ)小鼠簡介
- 肥胖型非胰島素依賴型糖尿病病人之非常低熱量飲食治療
頁籤選單縮合
| 題 名 | 脂肪肝的篩檢、診斷、臨床影響及治療=Screening, Diagnosis, Clinical Implications, and Management of Fatty Liver |
|---|---|
| 作 者 | 蘇東弘; | 書刊名 | 臺灣醫學 |
| 卷 期 | 30:1 2026.01[民115.01] |
| 頁 次 | 頁63-71 |
| 專 輯 | 雙重異位脂肪:從肝臟到胰臟的代謝風暴 |
| 分類號 | 415.59 |
| 關鍵詞 | 代謝異常; 肥胖; 糖尿病; 代謝異常脂肪肝病; 非酒精性脂肪肝病; Metabolic dysfunction; Obesity; Diabetes; Metabolic dysfunction-associated liver disease; Non-alcoholic fatty liver disease; NAFLD; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6320/FJM.202601_30(1).0008 |
| 英文摘要 | In recent years, both non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease have been increasing, becoming significant clinical problems. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the new terminology replacing NAFLD. The diagnosis of MASLD requires the presence of fatty liver along with cardiometabolic risk factors, such as a body mass index (BMI) >23 kg/m 2, high blood sugar, hypertension, high triglycerides, or low high-density lipoprotein (HDL) cholesterol. Alcohol consumption, specific genetic factors, medications, overweight, and metabolic dysfunction can worsen fatty liver disease. Currently, blood tests, ultrasound, and magnetic resonance imaging (MRI) are available to assess the degree of liver fibrosis and steatosis. Clinically, the FIB-4 index is recommended for evaluating liver fibrosis, as severe fibrosis worsens liver disease prognosis. The management of MASLD should focus on addressing cardiometabolic risk factors, steatosis or liver fibrosis. Lifestyle modifications, including dietary control and weight loss through exercise, are recommended to improve fatty liver and fibrosis. Resmetirom, a selective thyroid hormone receptor β agonist, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have been approved for the treatment of adult patients with moderate to advanced liver fibrosis associated with MASLD. Additionally, multiple drugs targeting different mechanisms are under development. Future efforts will focus on disease prevention, screening high-risk populations, early diagnosis, and timely treatment to reduce the burden of MASLD in Taiwan. |
本系統中英文摘要資訊取自各篇刊載內容。